Whitehawk Therapeutics, Inc.WHWKEarnings & Financial Report
Nasdaq
WHWK Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-19.5M
Net Profit
$-17.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.26
Whitehawk Therapeutics, Inc. Q3 2025 Financial Summary
Whitehawk Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-17.7M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-17.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Whitehawk Therapeutics, Inc. Annual Revenue by Year
Whitehawk Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $26.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $26.0M |
| 2023 | $24.4M |
| 2022 | $15.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.3M | $5.4M | $6.2M | $7.2M | $7.2M | $7.1M | $0 | $0 |
| YoY Growth | 21.0% | -8.8% | -0.4% | 21.0% | 14.4% | 33.5% | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $132.4M | $111.1M | $101.6M | $85.7M | $70.3M | $234.0M | $180.8M | $167.0M |
| Liabilities | $27.2M | $20.6M | $22.8M | $16.8M | $17.8M | $12.3M | $8.8M | $9.8M |
| Equity | $105.2M | $90.5M | $78.8M | $68.9M | $52.5M | $221.7M | $172.1M | $157.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.6M | $-19.7M | $-9.2M | $-15.7M | $-15.1M | $-11.9M | $-53.0M | $-15.4M |